Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 15;8(58):99024-99032.
doi: 10.18632/oncotarget.20931. eCollection 2017 Nov 17.

The association of matrix metalloproteinase-9 promoter polymorphisms with gastric cancer risk: a meta-analysis

Ziheng Peng #  1 , Jinhai Jia #  2 , Wenjian Gong  1 , Xuehan Gao  1 , Peiru Ma  1 , Zhucheng Jin  1 , Yue Fan  1 , Yanchu Li  1 , Xiaolin Zhang  3
Affiliations

The association of matrix metalloproteinase-9 promoter polymorphisms with gastric cancer risk: a meta-analysis

Ziheng Peng et al. Oncotarget. .

Abstract

Purpose: A variety of studies have observed that the single nucleotide polymorphisms (SNPs) matrix metalloproteinase-9 (MMP-9) gene may be associated with the risk of gastric cancer(GC), and a cytosine (C) to thymine (T) mutation at the -1562 site of the MMP-9 gene promoter is reported to be closely related to the susceptibility. However, because of the conflicting results of these studies, we undertook a systematic meta-analysis to assess the association between the SNPs and the risk of gastric cancer.

Materials and methods: A computerised literature search was conducted within the databases of PubMed, EMBASE, and ISI Web of Knowledge for studies on the genetic association of MMP-9-1562C/T and gastric cancer published from 2004 to 2015. The pooled odds ratio (OR) and 95% confidence intervals (CI) were estimated for each genotype using the dominant, recessive, co-dominant, and allelic models of the matrix metalloproteinase 9.

Results: Our analysis indicated a significant association of MMP-9-1562C/T with gastric cancer (dominant model [CT+TT/CC]: OR = 1.121, 95% CI = 0.965-1.304; recessive model [CC+CT/TT]: OR = 1.663, 95% CI = 1.148-2.408; co-dominant model [TT/CC]: OR = 1.666, 95% CI = 1.127-2.461; [CT/CC]: OR = 1.078, 95% CI = 0.923-1.259; allelic model [T/C]: OR = 1.150, 95% CI =1.014-1.304).

Conclusions: Our meta-analysis results demonstrated that MMP-9-1562C/T promoter polymorphisms increase the risk of developing gastric cancer.

Keywords: gastric cancer; matrix metalloproteinase 9; meta-analysis; polymorphisms susceptibility risk.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1. Flowchart summing the research and selection of articles for the meta-analysis
Figure 2
Figure 2. Meta-analysis forMMP9-1562 C/T polymorphism and gastric cancer susceptibility in allele genetic model
Figure 3
Figure 3. Meta-analysis for MMP9-1562 C/T polymorphism and gastric cancer susceptibility in co-dominant genetic model (TT)
Figure 4
Figure 4. Meta-analysis for MMP9-1562 C/T polymorphism and gastric cancer susceptibility in recessive genetic model
Figure 5
Figure 5. Meta-analysis for MMP9-1562 C/T polymorphism and gastric cancer susceptibility in dominant genetic model
Figure 6
Figure 6. Meta-analysis for MMP9-1562 C/T polymorphism and gastric cancer susceptibility in co-dominant genetic model (CT)
Figure 7
Figure 7. Funnel plots of the MMP-9 polymorphism studies: dominant model
No obvious funnel asymmetry was observed. Egger's test of the value from the funnel plot showed no statistical significance (p = 0.917).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105. - PMC - PubMed
    1. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010;25:371–379. - PubMed
    1. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin. 2005;131:19–25. - PubMed
    1. Jian C, Fei Q, Ying H, Lei Z. The study on the relationship between polymorphism of MMP-9 and gastric cancer. Modern Preventive Medicine. 2013:2329–2333.
    1. Verma S, Kesh K, Gupta A, Swarnakar S. An Overview of Matrix Metalloproteinase 9 Polymorphism and Gastric Cancer Risk. Asian Pac J Cancer P. 2015;16:7393–7400. - PubMed

LinkOut - more resources